Literature DB >> 6703686

Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

S M Harding, P E Williams, J Ayrton.   

Abstract

Cefuroxime axetil is a new orally absorbed prodrug of the antibiotic cefuroxime. The results of pharmacological studies in 52 healthy volunteers are presented. Intact cefuroxime axetil was not detected in the systemic circulation, indicating that deesterification to yield cefuroxime occurs rapidly after absorption. The bioavailability as measured by urinary recovery of cefuroxime was 40 to 50% if the drug was taken after food and 30% if the drug was taken after overnight fasting. Absorption was similar for three different formulations at 500 mg and independent of dose over the range of 250 mg to 1 g. When the drug was taken after food, serum levels and urinary recoveries were significantly greater for cefuroxime than for ampicillin, but when the drug was taken after fasting the values were similar for the two drugs. The kinetic behavior of cefuroxime axetil and ampicillin was not influenced by repeated dosing at 250 mg. Cefuroxime axetil was well tolerated. Although changes in bowel flora and habit were noted during repeated dosing, these changes were no greater than with ampicillin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6703686      PMCID: PMC185439          DOI: 10.1128/AAC.25.1.78

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  An introduction to mecillinam.

Authors:  W O Godtfredsen
Journal:  J Antimicrob Chemother       Date:  1977-07       Impact factor: 5.790

2.  Cefuroxime: human pharmacokinetics..

Authors:  R D Foord
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

3.  Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects.

Authors:  P G Welling; H Huang; P A Koch; W A Craig; P O Madsen
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

Review 4.  Gastrointestinal absorption of drugs.

Authors:  L F Prescott
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

5.  Antimicrobial usage in forty-three hospitals in England.

Authors:  D A Leigh
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

6.  Undescribed toxin in pseudomembranous colitis.

Authors:  H E Larson; J V Parry; A B Price; D R Davies; J Dolby; D A Tyrrell
Journal:  Br Med J       Date:  1977-05-14

7.  Bioavailability and metabolism of talampicillin.

Authors:  K H Jones; P F Langley; L J Lees
Journal:  Chemotherapy       Date:  1978       Impact factor: 2.544

  7 in total
  42 in total

Review 1.  Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Authors:  C Olivier
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.

Authors:  J Pace; A Bertasso; N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

3.  Pharmacokinetics of cefuroxime axetil and cefaclor: relationship of concentrations in serum to MICs for common respiratory pathogens.

Authors:  N C James; K H Donn; J J Collins; I M Davis; T L Lloyd; R W Hart; J R Powell
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers.

Authors:  H Lode; C Müller; K Borner; C E Nord; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 5.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

6.  Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

7.  Cefuroxime axetil for treatment of uncomplicated gonorrhea.

Authors:  A Gottlieb; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

10.  The relationship of diastereomer hydrolysis kinetics to shelf-life predictions for cefuroxime axetil.

Authors:  N A Nguyen
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.